BLAINJECTIONINJECTABLE
Approved
Apr 2009
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
SIMPONI (golimumab) by Johnson & Johnson is tumor necrosis factor receptor blocking activity [moa]. Approved for ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis and 1 more indications. First approved in 2009.
Drug data last refreshed 18h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SIMPONI (golimumab) is a monoclonal antibody TNF receptor blocker administered via injection, approved by the FDA in April 2009. It is indicated for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and ulcerative colitis by inhibiting tumor necrosis factor activity. The drug represents a cornerstone biologic therapy in the TNF inhibitor class, which has transformed the management of inflammatory and autoimmune diseases over the past 15 years.
$0.2BPart D
Mechanism of Action
Tumor Necrosis Factor Receptor Blocking Activity
Pharmacologic Class:
Tumor Necrosis Factor Blocker
Indications (4)
Worked on SIMPONI at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.